Subject(s)
Cold Temperature/adverse effects , Hypergammaglobulinemia/complications , Immunoglobulin G , Urticaria/etiology , Vasculitis, Leukocytoclastic, Cutaneous/etiology , Angioedema/etiology , Facial Dermatoses/etiology , Follow-Up Studies , Humans , Immunoglobulin G/analysis , Immunoglobulin kappa-Chains/analysis , Leg Dermatoses/etiology , Male , Middle AgedSubject(s)
Dermatomyositis/diagnosis , Panniculitis/diagnosis , Adult , Arm , Dermatomyositis/pathology , Diagnosis, Differential , Female , Humans , Panniculitis/pathologyABSTRACT
To further investigate the role of opioids in the regulation of the pituitary-adrenal axis we studied the effect of morphine and naloxone on human corticotropin-releasing hormone (hCRH)-induced ACTH, immunoreactive (ir) beta-endorphin, and cortisol release in normal subjects. Protocols: 1. 30 mg of a slow-release preparation of morphine or placebo was given orally 3 h prior to administration of hCRH (0.1 mg iv) (N = 7). 2. Naloxone (4 mg as bolus iv) or placebo was given 5 min prior to hCRH (N = 7). 3. Naloxone (4 mg iv as bolus followed by a continuous infusion of 6 mg over 75 min) or placebo was started 15 min prior to hCRH (N = 6). hCRH was injected at 11.00 h (protocol 1, 2) or at 17.00 h (protocol 3). Oral morphine not only suppressed basal hormone levels (P less than 0.02), but also the peak response to hCRH compared with placebo (cortisol: 270 +/- 50 vs 559 +/- 80 nmol/l; ACTH: 5.1 +/- 1.5 vs 13.1 +/- 2.7 pmol/l; ir beta-endorphin: 48.5 +/- 8.7 vs 88 +/- 14 pmol/l; mean +/- SEM, P less than 0.02). Similarly, the maximum incremental changes and the area under the curve were significantly reduced for all three hormones compared with placebo (P less than 0.05). After 4 mg of naloxone in the morning, no significant hormonal changes in response to hCRH were observed.(ABSTRACT TRUNCATED AT 250 WORDS)